qRT-PCR
A: Control cardiac tissue and AAV9-GFP, AAV9-SE, AAV9-SE siRNA, AAV9-AS, AAV9-AS siRNA infected cardiac tissue (right; ×200 magnification). B: qRT-PCR results for Kcna2 mRNA and Kcna2 AS expression levels in heart samples from adult rats treated with various constructs (n=4). *P<0.05 versus Control. C: Fluorescence images of primary cultured neonatal cardiomyocytes transfected with Adv-GFP. Brightfield image (left); fluorescent image (right; ×200 magnification). A, Fractional shortening (%) and ejection fraction (%) measured by echocardiography 8 weeks after the TAC procedure (n=6). control: sham surgery; CHF: rats with congestive heart failure; CHF+SE siRNA: knockdown of Kcna2 in rat hearts with CHF; CHF+SE: overexpression of Kcna2 in rat hearts with CHF; CHF+EGFP: green fluorescent protein (GFP) expressing control in rat hearts with CHF; CHF+AS: overexpression of Kcna2 AS in rat hearts with CHF; CHF+AS siRNA: knockdown of Kcna2 AS in rat hearts with CHF. ****P<0.0001. B, The mRNA levels of ANP, BNP, and MYH7 were assayed using real-time PCR in primary neonatal rat cardiomyocytes (n=6). ****P<0.0001. Figure S4 . Expression of Kcna2 AS and Kcna2 in human normal and heart failure tissue.
A: Kcna2 AS levels were increased and Kcna2 mRNA levels were reduced in the hearts of patients with CHF (n=3). *P<0.05 versus Control. Control: normal human; CHF: patients with congestive heart failure. B: Kcna2 protein levels were decreased in the hearts of patients with CHF (n=3). *P<0.05 versus Control. A, Representative traces of the Iks current in cardiomyocytes before or after treatment with 100 nM MTX. MTX: maurotoxin, a selective Kcna2 current inhibitor. B, I-V curve for cardiomyocytes (n=9 cells, 3 rats) before or after treatment with 100 nM MTX. The current density was plotted against each voltage. *P<0.05 versus the control group.
